Answers are grounded in this paper and cite their sources.
Stenotrophomonas maltophilia is difficult to treat due to the production of multiple intrinsic and acquired mechanisms of resistance. Trimethoprim-sulfamethoxazole (TMP-SMZ) and the fluoroquinolones have traditionally been considered the drugs of choice but are plagued by increasing resistance and adverse drug effects. The objective of this study was to evaluate the in vitro activities of 12 clinically relevant antimicrobials against clinical S. maltophilia isolates nonsusceptible to levofloxacin and/or TMP-SMZ.
No takes yet. Share an insight, caveat, or question.
Biagi et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: